EGFR and neoplasm: Diverse strategies based on anti-EGFR antibodies, like Cetuximab [7] and Nimotuzumab [5] induce tumor shrinkage or stabilization, mainly in combination with chemotherapy or radiotherapy, but resistant tumor variants rapidly emerge.